By admin 
When Kat Bryant Knudson was first diagnosed with limb girdle muscular dystrophy (LGMD), she was met with the devastating reality that no cure or effective treatment existed for her condition. For Knudson and the thousands of others living with progressive neuromuscular diseases, the passage of time is a relentless adversary. In the world of rare diseases, time is not a neutral factor; it is a measure of irreversible loss. Every month that a promising therapy is delayed by regulatory hurdles or clinical holds represents another month of muscle fibers dying, another month of lost mobility, and another step toward a life of total dependency.
Rare disease drug development is currently navigating an era of unprecedented scientific innovation. We are witnessing a transition from managing symptoms to addressing the underlying genetic causes of disease. Researchers are advancing gene therapies and targeted molecular treatments that were considered science fiction only a decade ago. These advancements rely heavily on sophisticated delivery mechanisms, such as viral vectors, which act as "molecular envelopes" to carry healthy genes into the body’s cells. As the United States strives to maintain its position as the global leader in biotechnology, the Food and Drug Administration (FDA) finds itself at a critical juncture. With new leadership at the helm, the agency has an opportunity to modernize its oversight by utilizing innovative trial designs and regulatory tools that reflect the complexities of 21st-century medicine.
A central pillar of this modernization effort was supposed to be the utilization of "platform technology designations." This concept was codified by Congress through the Food and Drug Omnibus Reform Act (FDORA) of 2022. The logic behind the platform designation is both sensible and elegant: if a pharmaceutical company uses the same underlying technology—such as the same adeno-associated virus (AAV) vector—to deliver different genetic payloads across multiple diseases, the regulatory process should reflect that continuity. Rather than forcing a developer to "start from scratch" with every new application, the FDA should allow data and safety profiles from one program to inform and accelerate the review of subsequent programs using the same platform. In theory, platforms are about efficiency, predictability, and moving the needle forward for patients who do not have years to wait.
However, the implementation of these tools has become a source of growing alarm for patients, clinicians, advocacy organizations, and biotechnology leaders. Critics argue that the FDA’s recent actions have created an environment of heightened uncertainty, where the agency is failing to consistently apply the regulatory flexibility that Congress intended. Instead of accelerating treatments, some argue the FDA is misapplying these tools in a way that creates a "one-way street" of risk: while safety concerns in one program are used to justify sweeping holds across an entire platform, the positive data and accumulated safety knowledge from successful trials are rarely used to expedite related programs. For the LGMD community, this regulatory inconsistency is currently playing out with tragic consequences.
The case of Sarepta Therapeutics serves as a primary example of this "inside-out" logic. In June 2025, the FDA awarded Sarepta a landmark platform technology designation for the viral vector utilized in its muscular dystrophy gene therapy programs. This included a therapy specifically designed for LGMD2E/R4, a subtype of limb girdle muscular dystrophy characterized by the lack of a protein called beta-sarcoglycan. The designation was hailed as a breakthrough for the rare disease community, signaling a new era of regulatory speed.
The optimism was short-lived. Barely a month after the designation was granted, the FDA revoked it and placed a clinical hold across all of Sarepta’s trials utilizing that specific vector. The move followed the tragic deaths of three nonambulatory individuals: two patients with Duchenne Muscular Dystrophy (DMD) and one patient with LGMD 2D/R3. These fatalities were devastating blows to the community, and the suspension of trials was an appropriate immediate response to allow researchers to reassess the benefit-risk profile, particularly for patients who have already lost the ability to walk. The safety of participants is, and must remain, the paramount concern in any clinical trial.
However, the subsequent regulatory decisions have left the LGMD community in a state of confusion and despair. While the clinical hold remained in place for the LGMD2E/R4 program, the FDA eventually allowed dosing to resume for the related Duchenne therapy—built on the exact same platform—for ambulatory patients (those who can still walk). The logic was that the risk profile for ambulatory patients was sufficiently understood and distinct from that of nonambulatory patients. Yet, this same nuance was not extended to the LGMD2E/R4 program. Despite the Phase 3 trial for this subtype being nearly complete and the company preparing for an approval filing, the entire program remains on hold for both ambulatory and nonambulatory patients.
This discrepancy highlights a fundamental flaw in the current application of platform designations. The agency used the "platform" concept to justify stopping every program associated with the vector when a risk was identified, but it failed to use that same platform logic to restore access for LGMD patients when the safety of ambulatory patients was validated in the Duchenne trials. This "asymmetric extrapolation" means that risk travels quickly across diseases, but progress and benefit-risk justifications travel slowly, if at all.
This is not an isolated incident. In January, the FDA placed a clinical hold on a gene therapy for MPS I (Hurler syndrome), a severe metabolic disorder, after a tumor was discovered in a young patient. Citing shared risk, the FDA then extended that hold to a separate program for MPS II (Hunter syndrome), which utilized a similar delivery method. This extension occurred despite the fact that 32 patients in the Hunter syndrome program had been treated without similar adverse outcomes, some having been dosed nearly seven years prior. While the FDA recently lifted the hold on the Hunter syndrome program and reconsidered its approval pathway, the delay caused significant anxiety and stalled potential life-saving interventions for a fatal pediatric disease.
The pattern emerging from these cases suggests a regulatory framework that is reactive rather than holistic. When a safety signal appears, the FDA extrapolates freely across products and diseases. But when years of accumulated knowledge, refined dosing, and successful patient selection data are presented, sponsors are often told that such information cannot be transferred from one program to another. For patients with ultra-rare diseases like LGMD2E/R4, this inconsistency is particularly perilous. Because these patient populations are so small, there is little incentive for other developers to step in if a program is stalled by regulatory ambiguity. If the current developer cannot find a path forward, the entire disease community may be left without any therapeutic options for a generation.
Furthermore, the scientific community is making rapid strides in understanding how to mitigate the risks associated with AAV gene therapies. There is a growing consensus among experts that many of the severe adverse events, such as liver hepatotoxicity, can be managed or prevented with enhanced immunosuppression regimes. Specifically, the use of medications like sirolimus is increasingly viewed as a vital tool in protecting patients during the critical window following gene therapy administration. The question facing regulators is how many fatalities or clinical holds must occur before these advanced safety protocols are integrated into standardized trial designs.
The stakes could not be higher. For individuals with progressive rare diseases, the FDA must balance two distinct types of risk: the risk of treatment-related harm and the risk of irreversible harm caused by regulatory delay. In many cases, the "risk of doing nothing" is a guaranteed progression toward disability and death. A regulatory system that only accounts for the former while ignoring the latter is not truly protecting patients; it is inadvertently condemning them to the natural, devastating course of their disease.
As Congress prepares for the reauthorization of the Prescription Drug User Fee Act (PDUFA), there is an urgent need for legislative clarity. Advocacy groups, led by organizations like The Speak Foundation, are calling on lawmakers to send a clear message to the FDA. Congress expects the agency to fully utilize the provisions of the 21st Century Cures Act and FDORA, including novel trial designs and the effective, consistent application of platform technologies.
A consistent framework is required to govern how risk and knowledge are transferred across platforms. This framework must be predictable, transparent, and grounded in the reality of the patient experience. It must recognize that while safety is non-negotiable, flexibility is essential when dealing with ultra-rare populations where traditional large-scale trials are impossible.
Kat Bryant Knudson’s plea is a reflection of a broader sentiment within the rare disease community: patients cannot wait for a perfect system, but they deserve a logical one. The promise of gene therapy is the promise of a future where genetic "mistakes" can be corrected. But that future remains out of reach if the regulatory hurdles are so inconsistent that they stifle the very innovation they were meant to foster. The FDA must prioritize rare disease treatments, not by cutting corners on safety, but by ensuring that the "elegant" idea of platform technology actually works in practice to save lives. For those watching their muscles waste away while a promising therapy sits on a shelf due to administrative inconsistency, the time for reform is now.
